BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Novo Nordisk Stock Rises as Rival’s Weight-Loss Drug Trial Results Fall Short
Novo Nordisk Stock Rises as Rival’s Weight-Loss Drug Trial Results Fall Short
6
1
BTCCSquare news:
Novo Nordisk shares climbed nearly 5% on Friday, outperforming the broader market index's 0.8% gain. The rally came after Eli Lilly reported phase 3 trial results for its oral weight-loss drug orforglipron, which showed a 12% average body weight reduction—below the anticipated 15%.
Investors viewed the results as favorable for Novo Nordisk's injectable Wegovy, despite Lilly's positive framing of the data. The Danish pharmaceutical firm benefited from comparative analysis suggesting its treatment may offer superior efficacy in the competitive GLP-1 drug market.
By:
